Gynecology

FRIDAY, NOVEMBER 22

08:30-10:00 HPV
Hall C
Capsule As the cervical cancer elimination campaign takes shape, several initiatives are being considered in practical contexts. The session will explore some of them and specifically the role of the gynecologists
Chairperson Xavier Bosch, Spain
Panelists Mario Poljak, Slovenia
Maaike Bleeker, Netherlands
Pier Luigi Lopalco, Italy
Kevin Pollock, UK
  • General frame on cervical cancer elimination
  • Female HPV vaccine acceptance. Vaccination achievements
  • Vaccination crisis
  • Safety of the vaccines and the Cochrane dispute
  • Male vaccination. Expected penetrance and impact
  • Vaccinating women in screening ages (25-45+)
  • Transition to HPV primary screening in Europe
  • Self-sampling initiatives in Europe and in developing countries
  • HPV testing technology. Validation of tests
  • Questions from the  audience
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-11:50 INDUTRY SUPPORTED SESSION
Hall C
11:50-12:10 BREAK
EXIBITION AREA
12:10-13:40 VULVO-VAGINAL ATROPHY / GSM
Hall C
Capsule Laser treatment for vulvo-vaginal atrophy, a transit relief or paradigm shift?
Chairpersons Santiago Palacios, Spain
Alessandra Graziottin, Italy
12:10-12:55 Debate: Do we need RCTs for laser in VVA/GSM or are observational data enough?
For RCTS: Santiago Palacios, Spain
For observational/registry data: Marco Gambacciani, Italy
Discussion
12:55-13:20 Can lasers reduce overactive bladder symptoms?
Zdenko Vizintin, Slovenia
13:20-13:40 VVA – Do we need to change nomenclature to GSM?
Bari Kaplan, Israel
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 BREAST CANCER
Hall C
Capsule Breast cancer epidemic and hormonal replacement: What is the relationship?
Chairpersons Herjan Coelingh Bennink, Netherlands
Nicholas Panay, UK
14:30-14:55 Can HRT be individualized to reduce the incidence of breast cancer?
Mark Brincat, Malta
14:55-15:15 Prescribing Contraception and HRT in BRCA carriers
Anne Gompel, France
15:15-16:00 Debate: Does HRT increase the risk of breast cancer?
Yes: Serge Rozenberg, Belgium
No: Mark Brincat, Malta
Discussion
16:00-16:30 Special Countercurrent lecture:
Treatment of advanced breast cancer with high dose estrogens
Herjan Coelingh Bennink, Netherlands
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-17:55 PERIMENOPAUSAL SIDE EFFECTS AND MANAGEMENT Hall C
Capsule Perimenopausal and menopausal side effect
Chairpersons Ann Gompel, France
Alessandra Graziottin, Italy
16:50-17:10 Hot flushes, peripheral or central nervous system?
Mark Brincat, Malta
17:10-17:35 Update on isoflavones in menopause
Christian Egarter, Austria
17:35-17:55 Endometriosis in the menopause
Marco Gambacciani, Italy

SATURDAY, NOVEMBER 23

08:30-10:00 PREDICTION OF MENOPAUSE AND RISK FACTORS
Hall C
Capsule Can we predict and prevent menopausal complications and side effects?
Chairpersons Nicholas Panay, UK
Christian Egarter, Austria
08:30-09:00 Is there an increased CVD risk in PCOS women?
Roger A. Lobo, USA
09:00-09:30 Does anti-Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study
Joop Laven, Netherlands
09:30-10:00 Cardiovascular impact of progestins in women
Christian Egarter, Austria
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-11:50 UTERINE ANOMALIES; GYNE-ONCOLOGY
Hall C
Capsule Counselling on protection of fertility became a standard of care
Chairpersons Ludwig Kiesel, Germany
Alessandra Graziottin, Italy
  UTERINE ANOMALIES
10:20-10:45 Symmetric and non-symmetric uterine anomalies
Leila Adamyan, Russia
10:45-11:05 Counseling young women with uterovaginal anomalies
George Creatsas, Greece
  GYNE-ONCOLOGY
11:05-11:30 Protecting reproductive potential in (gynecological) cervical cancer
Pierluigi Benedetti Panici, Italy
11:30-11:50 Protecting reproductive potential in ovarian cancer
Catherine Uzan, France
11:50-12:10 BREAK
EXIBITION AREA
12:10-13:40 ADVANCES IN HORMONAL TREATMENT
Hall C
Capsule What is the ideal SERMs and SPRMs
Chairperson Mark Brincat, Malta
George Creatsas, Greece
12:10-12:40 New progestogens / SPRMS: What are the possibilities?
Christian Egarter, Austria
12:40-13:10 New SERMS / TSECS: Can they be an HRT substitute?
Santiago Palacios, Spain
13:10-13:40 Targeting HRT:  From indication to personalization
Marco Gambacciani, Italy
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 PREVENTION OF MENOPAUSAL SYMPTOMS
Hall C
Capsule Are we back to consensus in HRT?
Chairperson Santiago Palacios, Spain
14:30-14:55 Should we use HRT for “prevention” in postmenopausal women
Roger A. Lobo, USA
14:55-15:15 How to overcome hormone resistance in women with breast cancer?
Ludwig Kiesel, Germany
15:15-16:00 Debate: Should androgens be routinely offered to optimize quality of life in menopause?
For:  Alessandra Graziottin, Italy
Against: Lydia Marie-Scemama, France
Discussion
16:00-16:30 Special Countercurrent lecture:
Testosterone: The need for a new consensus
Nicholas Panay, UK
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-18:20 PERIMENOPAUSAL CONTRACEPTION
Hall C
Capsule Oral contraception until menopause?
Chairpersons Mark Brincat, Malta
Bari Kaplan, Israel
16:50-17:10 Perimenopausal contraception: What are the current options?
Christian Egarter, Austria
17:10-17:35 What are the future contraceptive possibilities?
Phillipe Bouchard, France
17:35-17:55 Minimizing cardiovascular risks of perimenopausal contraception
Lydia Marie-Scemama, France
17:55-18:20 Optimizing psychosexual health with perimenopausal contraception
Alessandra Graziottin, Italy